Q4 & FY2023 presentation

You say that you are ”restricted” about what you can say about what will happen with your unused rights. I understand that. And you say that existing shareholders would help the company by exercise their rights instead of buying the share, which is way below 18 DKK. There is a big hole here in your reasoning, its like you expect investors to be philantropists and not interesting making money in a transparent company. Right now the rights issue is up in the air and Im afraid it to be a failure. I would much like you to convince me - with your best argument - in investing, because right now its like buying in the blind.

With all the interest in this field, How active are you working with establishing partnerships and connecting with potential partners to make them aware of you?

Dear Ulrich and Andreas,

Could you please touch on your feeling/knowledge as to this rights issue being a success? Do you have any takers for any rights that may not be excercised in this issue? Hereunder the rights that you yourselves will not use, and the rights that private investors will not use.

If the stock continues to trade below around 16 DKK, then do you have a plan for getting investors to buy into 18 DKK in the capital increase?

How would you rate the chances of a future partnership and/or buyout of the company?

Why haven’t the company released the result from the awaited uTREAT result in H & N and Neuroendocrine tumors yet?

When do you expect to need funding again after this round of funding?

Dear Andreas and Ulrich.

Thank you for the latest progress. But there is a big elephant in the room. You two own half the company and will get 10 milion rights, almost all will not be exercised of you in the rights issue. What will happen with your unused rights?

Are you done developing the uTRACE-category alone on the specific cancer types (Other than prostate) And will you then only proceed with uTRACE as part of the theranostic platform?

Could you please ellaborate on the reason to suddenly add pancreatic cancer to your uTREAT pipeline?

Can you elaborate on what you will use the 51 DKKm in new capital for. How will it speed up the development of your pipeline and which areas will be in focus?